Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond
P.N. Praveen Rao,Edward E. Knaus +1 more
Reads0
Chats0
TLDR
This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects.Abstract:
Purpose. NSAIDs constitute an important class of drugs with therapeutic applications that have spanned several centuries. Treatment of inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) starting from the classic drug aspirin to the recent rise and fall of selective COX-2 inhibitors has provided an enthralling evolution. Efforts to discover an ultimate magic bullet to treat inflammation continues to be an important drug design challenge. This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects. Methods. Literature data is presented describing important discoveries pertaining to the sequential development of classical NSAIDs and then selective COX-2 inhibitors, their mechanism of action, the structural basis for COX inhibition, and recent discoveries. Results. A brief history of the development of NSAIDs and the market withdrawal of selective COX-2 inhibitors is explained, followed by the description of prostaglandin biosynthesis, COX isoforms, structure and function. The structural basis for COX-1 and COX-2 inhibition is described along with methods used to evaluate COX-1/COX-2 inhibition. This is followed by a section that encompasses the major chemical classes of selective COX-2 inhibitors. The final section describes briefly some of the recent advances toward developing effective anti-inflammatory agents such as nitric oxide donor NO-NSAIDs, dual COX/LOX inhibitors and anti-TNF therapy. Conclusions. A great deal of progress has been made toward developing novel anti-inflammatory agents. In spite of the tremendous advances in the last decade, the design and development of a safe, effective and economical therapy for treating inflammatory conditions still presents a major challenge.read more
Citations
More filters
Journal ArticleDOI
Anti-inflammatory and antioxidant properties of a novel resveratrol-salicylate hybrid analog.
Fahad S. Aldawsari,Rafael Pazinatto Aguiar,Luiz Alexandre Marques Wiirzler,Rodrigo Aguayo-Ortiz,Naif Aljuhani,Roberto Kenji Nakamura Cuman,José L. Medina-Franco,Arno G. Siraki,Carlos A. Velázquez-Martínez +8 more
TL;DR: A novel compound (C10) is identified as a potent anti-inflammatory agent and because of the proven association between cancer, inflammation, and oxidative stress, it is believed that C10 is a promising chemopreventive molecule.
Journal ArticleDOI
Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction
TL;DR: In this article, the up-to-date findings regarding definitive/possible causes and mechanisms of inflammation-related carcinogenesis derived from experimental and clinical studies are summarized and 10 strategies, as well as candidate agents for the prevention, are proposed.
Journal ArticleDOI
Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity.
Astrid S. Kahnt,Florian Rörsch,Olaf Diehl,Bettina Hofmann,Christoph Lehmann,Christoph Lehmann,Svenja Dorothea Steinbrink,Carlo Angioni,Gerd Geisslinger,Sabine Grösch,Dieter Steinhilber,Thorsten J. Maier +11 more
TL;DR: It is shown that LTRA inhibit PGE2 formation in cytokine-stimulated Hela and A549 carcinoma cells and in lipopolysaccharide -stimulated human leukocyte preparations and LTRA may serve as new scaffolds for the development of potent, selective and well tolerated mPGES-1 inhibitors.
Journal ArticleDOI
Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period
TL;DR: To determine the effectiveness of a single dose of an oral NSAID for relief of acute perineal pain in the early postpartum period, 28 studies that examined 13 different NSAIDs were examined and involved 4181 women.
Journal ArticleDOI
Rethinking the role of opioids in the outpatient management of chronic nonmalignant pain
TL;DR: Impacted patient selection through identification of risk factors, urine drug testing, and access to prescription monitoring programs has been shown to effectively improve care and implementation of opioid allocation strategies has the potential to encourage appropriate opioid use and improve patient care.
References
More filters
Journal ArticleDOI
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
TL;DR: Experiments with guinea-pig lung suggest that some of the therapeutic effects of sodium salicylate and aspirin-like drugs are due to inhibition of the synthesis of prostaglandins.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Cyclooxygenases: Structural, cellular, and molecular biology
TL;DR: This review examines how the structures of these enzymes relate mechanistically to cyclooxygenase and peroxidase catalysis, and how differences in the structure of PGHS-2 confer on this isozyme differential sensitivity to COX-2 inhibitors.
Journal ArticleDOI
Cyclooxygenases 1 and 2
TL;DR: The discovery ofCOX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1, which may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.